China’s National Medical Products Administration approved Innovent Biologics Inc.’s NDA for Tabosun (ipilimumab N01, IBI-310) in combination with sintilimab as neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high or mismatch repair deficient colon cancer.
Shenzhen Targetrx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to Raf kinase B (V600E mutant)-targeting moiety through linker reported to be useful for the treatment of cancer.
Jiangsu Simcere Biologics Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising an antibody huAb-H3aL3-IgG1 targeting cadherin-17 (CDH17) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SIM-0610 to be studied in patients with locally advanced or metastatic solid tumors.
Jiangsu Simcere Biologics Co. Ltd. has described bispecific antibody-drug conjugates (ADC) comprising a bispecific human antibody targeting hepatocyte growth factor receptor (HGFR; MET) and epidermal growth factor receptor (EGFR; HER1; erbB1), covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Alicorn Pharmaceutical Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Shanghai Best-Link Bioscience LLC has described polymer-drug conjugates comprising a polymer covalently linked to a cytotoxic drug through a linker and its nanoparticles reported to be useful for the treatment of cancer.
